Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

This is a Phase 2 study testing a new combination of three drugs — SR-8541A, botensilimab, and balstilimab — for people with metastatic colorectal cancer that has not responded to standard treatments. This type of colorectal cancer (called MSS or microsatellite stable) is typically resistant to immunotherapy, and this combination is designed to overcome that resistance. **You may be eligible if...** - You are 18 or older - You have confirmed advanced (unresectable or metastatic) colorectal cancer that is microsatellite stable (MSS) or proficient mismatch repair (pMMR) - You have received at least one prior chemotherapy regimen for metastatic disease - Your general health score (ECOG) is 0 or 1 - Your kidneys, liver, and blood counts are in adequate range **You may NOT be eligible if...** - You have previously received immunotherapy (PD-1, PD-L1, or CTLA-4 drugs) - You have recently had bowel obstruction or refractory ascites - You have active autoimmune disease requiring systemic treatment in the past 2 years - You have significant heart disease, active infections, or HIV/Hepatitis B or C - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.